Intrinsiqq
Pharmacyte Biotech Inc. logo

Pharmacyte Biotech Inc. Financials

PMCB

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 17 available years
Income Statement
TTM
APR 2026
APR 2025
APR 2024
APR 2023
APR 2022
~10.7:1 split
Revenues
Revenue$0$0$0$0$0$0
General & Administrative$5$5$4$6$1$1
Research & Development$0$0$0$0$0$1
Total Operating Expenses$7$7$4$9$6$4
Operating Income-$7-$7-$4-$9-$6-$4
Non-Operating
Net Interest Expense––––$0-$0
Other Non-Operating Income (Expense)-$9-$13$35$9$2$0
Income Tax Expense–$0$0$0$0$0
Net Income
Net Income-$16-$19$31$0-$4-$4
Per Share Data
Revenue Per Share$0.00$0.00$0.00$0.00$0.00$0.00
EPS (Basic)-$2.08-$2.77$3.19-$1.80-$0.22-$0.27
EPS (Diluted)-$2.40-$2.77$3.19-$1.80-$0.22-$0.27
Weighted Avg Shares (Basic)10.7M8.4M7.3M9.6M19.5M15.5M
Weighted Avg Shares (Diluted)10.7M8.4M7.3M9.6M19.5M15.5M
Shares Outstanding10.7M8.4M7.3M9.6M19.5M15.5M

Pharmacyte Biotech (PMCB) financials: revenue, profit and margins

Pharmacyte Biotech (PMCB) generated about $0.00 in revenue and -$16 million in net income over the trailing twelve months, growing at roughly -68.9% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Pharmacyte Biotech's (PMCB) revenue?+

Pharmacyte Biotech generated about $0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -68.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Pharmacyte Biotech profitable?+

Pharmacyte Biotech reported about -$16 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Pharmacyte Biotech growing?+

Pharmacyte Biotech's revenue has compounded at roughly -68.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside PMCB's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 11 Sept 2026, covering the period ending 31 Jul 2026, as reported to the SEC. Data last refreshed 15 Sept 2026. How this is calculated.

Fiscal year ends Apr.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PMCB

CompareIntrinsic value
CSBRChampions Oncology, Inc.
$4.35-1.14%26
PLURPluri Inc.
$0.94-3.09%30
TECHBio-Techne Corporation
$72.67-0.04%41
OTLKOutlook Therapeutics Inc.
$0.39-3.32%10
SCLXScilex Holding Company
$0.57-12.95%0
ELUTElutia Inc.
$0.89+8.54%20
CRISCuris Inc.
$0.44-7.21%35
INBXInhibrx Biosciences, Inc.
$68.97-7.21%18

Spot a number that looks wrong? Check it in PMCB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PMCB

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.